Floatz logo

gc101

Melanoma Metastatic

Inge Marie Svanegene_therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Melanoma Metastatic cohort.

Asset / SponsorPhaseRating
Prolgolimab
Biocad
Phase 3BB
Bcd-217
Biocad
Phase 3BB
Fludarabine
East Metropolitan Health Service, Australia
Phase 2CCC
CARMUSTINE
Western Regional Medical Center
Phase 2CCC
PEGFILGRASTIM
Western Regional Medical Center
Phase 2CCC
bi-1607
BioInvent International AB
Phase 1/2CC
Ny-Eso-1 Tcr Redirected Autologous T Cell Product
Centre Hospitalier Universitaire Vaudois
Phase 1CC
[225ac]ac-a9-3408
Alpha-9 Oncology USA Inc.
Phase 1CC

Same molecule, other indications

gc101 is also rated in:

SMA - Spinal Muscular AtrophyDormant
BB
Indicative ·
66 / 100
View asset →
Adverse Drug EventDormant
B
Indicative ·
60 / 100
View asset →
Tumor Infiltrating LymphocytesDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →